153 related articles for article (PubMed ID: 32411606)
1. Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Gao Y; Liu B; Feng L; Sun B; He S; Yang Y; Wu G; E G; Liu C; Gao Y; Zhang E; Zhu B
Front Oncol; 2020; 10():644. PubMed ID: 32411606
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Targeting JUN, CEBPB and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma.
Gao Y; Liu B; Feng L; Sun B; He S; Yang Y; Wu G; E G; Liu C; Gao Y; Zhang E; Zhu B
Front Oncol; 2024; 14():1392899. PubMed ID: 38715787
[TBL] [Abstract][Full Text] [Related]
3. Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Gao Y; Liu B; Feng L; Sun B; He S; Yang Y; Wu G; E G; Liu C; Gao Y; Zhang E; Zhu B
Front Oncol; 2019; 9():33. PubMed ID: 30775317
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide.
Llaguno-Munive M; León-Zetina S; Vazquez-Lopez I; Ramos-Godinez MDP; Medina LA; Garcia-Lopez P
Front Oncol; 2021; 11():675806. PubMed ID: 33828996
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.
Di Villeneuve L; Souza IL; Tolentino FDS; Ferrarotto R; Schvartsman G
Front Oncol; 2021; 11():669486. PubMed ID: 33898325
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma.
Cheng F; Zhang P; Xiao Q; Li Y; Dong M; Wang H; Kuang D; He Y; Duan Q; Mao F; Wang B; Guo D
Front Oncol; 2020; 10():591112. PubMed ID: 33102241
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
Front Oncol; 2020; 10():684. PubMed ID: 32426288
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum: Cytotoxic Effects of Arsenite in Combination With Gamabufotalin Against Human Glioblastoma Cell Lines.
Yuan B; Xu K; Shimada R; Li J; Hayashi H; Okazaki M; Takagi N
Front Oncol; 2021; 11():778834. PubMed ID: 34692557
[TBL] [Abstract][Full Text] [Related]
9. Corrigendum: Machine Learning-Based Analysis of Magnetic Resonance Radiomics for the Classification of Gliosarcoma and Glioblastoma.
Qian Z; Zhang L; Hu J; Chen S; Chen H; Shen H; Zheng F; Zang Y; Chen X
Front Oncol; 2021; 11():774369. PubMed ID: 34737968
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells
Chen J; Zeng Y; Wu R; Xuan Y; Jiang M; Teng H
Front Oncol; 2021; 11():676647. PubMed ID: 33928040
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum: PHF20 promotes glioblastoma cell malignancies through a
Ma Q; Long W; Xing C; Jiang C; Su J; Wang HY; Liu Q; Wang R
Front Oncol; 2023; 13():1157694. PubMed ID: 37035210
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Highly invasive fluorescent/bioluminescent patient-derived orthotopic model of glioblastoma in mice.
Yuzhakova D; Kiseleva E; Shirmanova M; Shcheslavskiy V; Sachkova D; Snopova L; Bederina E; Lukina M; Dudenkova V; Yusubalieva G; Belovezhets T; Matvienko D; Baklaushev V
Front Oncol; 2022; 12():1040637. PubMed ID: 36248972
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum: Metabolic Reprogramming During Multidrug Resistance in Leukemias.
Vidal RS; Quarti J; Rodrigues MF; Rumjanek FD; Rumjanek VM
Front Oncol; 2018; 8():441. PubMed ID: 30460192
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum: Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel.
Krauze AV; Sierk M; Nguyen T; Chen Q; Yan C; Hu Y; Jiang W; Tasci E; Zgela TC; Sproull M; Mackey M; Shankavaram U; Meerzaman D; Camphausen K
Front Oncol; 2024; 14():1348105. PubMed ID: 38544831
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma.
Chen Y; Li R; Zhu Y; Zhong S; Qian J; Yang D; Jurczyszyn A; Beksac M; Gu C; Yang Y
Front Oncol; 2021; 11():736373. PubMed ID: 34368005
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Metabolic Dependencies in Pancreatic Cancer.
Vaziri-Gohar A; Zarei M; Brody JR; Winter JM
Front Oncol; 2018; 8():672. PubMed ID: 30805300
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies.
Cao J; Zhang M; Wang B; Zhang L; Zhou F; Fang M
Front Oncol; 2021; 11():745052. PubMed ID: 34485165
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum: HypoxamiRs Profiling Identify miR-765 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells.
Salinas-Vera YM; Gallardo-Rincón D; García-Vázquez R; Hernández-de la Cruz ON; Marchat LA; González-Barrios JA; Ruíz-García E; Vázquez-Calzada C; Contreras-Sanzón E; Resendiz-Hernández M; Astudillo-de la Vega H; Cruz-Colin JL; Campos-Parra AD; López-Camarillo C
Front Oncol; 2020; 10():889. PubMed ID: 32582552
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.
Lai Y; Feng B; Abudoureyimu M; Zhi Y; Zhou H; Wang T; Chu X; Chen P; Wang R
Front Oncol; 2020; 10():277. PubMed ID: 32195187
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma.
Zhang MX; Wang L; Zeng L; Tu ZW
Front Oncol; 2021; 11():670714. PubMed ID: 33816321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
